Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline

Violette Da Cunha(Centre National de la Recherche Scientifique), Mark R. Davies(The University of Queensland), Pierre-Emmanuel Douarre(Centre National de la Recherche Scientifique), Isabelle Rosinski‐Chupin(Centre National de la Recherche Scientifique), Immaculada Margarit(Novartis (Italy)), Sébastien Spinali(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Tim Perkins(Novartis (Italy)), P Lechat(Institut Pasteur), Nicolas Dmytruk(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Elisabeth Sauvage(Centre National de la Recherche Scientifique), Laurence Ma(Institut Pasteur), Benedetta Romi(Novartis (Italy)), Magali Tichit(Institut Pasteur), María José López Sánchez(Centre National de la Recherche Scientifique), Stéphane Descorps‐Declère(Institut Pasteur), Erika Souche(Institut Pasteur), Carmen Buchrieser(Centre National de la Recherche Scientifique), Patrick Trieu‐Cuot(Centre National de la Recherche Scientifique), Ivan Moszer(Institut Pasteur), Dominique Clermont(Institut Pasteur), Domenico Maione(Novartis (Italy)), Christiane Bouchier(Institut Pasteur), David J. McMillan(University of the Sunshine Coast), Julian Parkhill(Wellcome Sanger Institute), John L. Telford(Novartis (Italy)), Gordan Dougan(Wellcome Sanger Institute), Mark J. Walker(The University of Queensland), Pierette Melin, Antoaneta Decheva(National Center of Infectious and Parasitic Diseases), Bogdan Petrunov(National Center of Infectious and Parasitic Diseases), Paula Kriz(National Institute of Public Health), Reinhard Berner(University Medical Center Freiburg), Anna Büchele(University Medical Center Freiburg), Markus Hufnagel(University Medical Center Freiburg), Mirjam Kunze(University Medical Center Freiburg), Roberta Creti(Istituto Superiore di Sanità), Lucilla Baldassarri(Istituto Superiore di Sanità), Graziella Orefici(Istituto Superiore di Sanità), Alberto Berardi(Azienda Ospedaliero-Universitaria di Modena), Javier Rodríguez Granger(Hospital Universitario Virgen de las Nieves), Manuel de la Rosa Fraile(Hospital Universitario Virgen de las Nieves), Baharak Afshar(Public Health England), Androulla Efstratiou(Public Health England), Matthew T. G. Holden(Wellcome Sanger Institute), Claire Poyart(Délégation Paris 5), Philippe Glaser(Centre National de la Recherche Scientifique)
Nature Communications
August 4, 2014
Cited by 248Open Access
Full Text

Abstract

Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal of the digestive and genitourinary tracts of humans that emerged as the leading cause of bacterial neonatal infections in Europe and North America during the 1960s. Due to the lack of epidemiological and genomic data, the reasons for this emergence are unknown. Here we show by comparative genome analysis and phylogenetic reconstruction of 229 isolates that the rise of human GBS infections corresponds to the selection and worldwide dissemination of only a few clones. The parallel expansion of the clones is preceded by the insertion of integrative and conjugative elements conferring tetracycline resistance (TcR). Thus, we propose that the use of tetracycline from 1948 onwards led in humans to the complete replacement of a diverse GBS population by only few TcR clones particularly well adapted to their host, causing the observed emergence of GBS diseases in neonates.


Related Papers

No related papers found

Powered by citation graph analysis